Detalhe da pesquisa
1.
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.
N Engl J Med
; 389(23): 2162-2174, 2023 Dec 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38055253
2.
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.
Lancet
; 403(10434): 1341-1350, 2024 Apr 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38521086
3.
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.
N Engl J Med
; 386(5): 437-448, 2022 02 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35045221
4.
Targeting CXCR4 impaired T regulatory function through PTEN in renal cancer patients.
Br J Cancer
; 2024 May 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38704478
5.
Reproductive outcomes after conservative treatment in early and advanced stage MOGCTs.
Gynecol Oncol
; 181: 28-32, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38104526
6.
Alpelisib for PIK3CA-mutated advanced gynecological cancers: First clues of clinical activity.
Gynecol Oncol
; 183: 61-67, 2024 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38518529
7.
Real world data of niraparib in platinum sensitive relapsed ovarian cancer: A multicenter experience of the MITO group.
Gynecol Oncol
; 184: 24-30, 2024 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38277918
8.
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.
Lancet Oncol
; 24(3): 286-296, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37052965
9.
Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer.
J Transl Med
; 21(1): 75, 2023 02 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36737752
10.
Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial.
Gynecol Oncol
; 172: 72-77, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36965291
11.
Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial.
Gynecol Oncol
; 172: 121-129, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37030280
12.
Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer.
Gynecol Oncol
; 170: 300-308, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36758420
13.
Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer.
Gynecol Oncol
; 177: 20-31, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37625235
14.
Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study.
Gynecol Oncol
; 175: 182-189, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37355448
15.
Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100.
Gynecol Oncol
; 178: 119-129, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37862791
16.
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors.
Int J Gynecol Cancer
; 33(6): 922-928, 2023 06 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36759000
17.
Endometrial carcinosarcoma.
Int J Gynecol Cancer
; 33(2): 147-174, 2023 02 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36585027
18.
Gestational choriocarcinoma.
Int J Gynecol Cancer
; 33(10): 1504-1514, 2023 10 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37758451
19.
Homologous Recombination Deficiency (HRD) Scoring, by Means of Two Different Shallow Whole-Genome Sequencing Pipelines (sWGS), in Ovarian Cancer Patients: A Comparison with Myriad MyChoice Assay.
Int J Mol Sci
; 24(23)2023 Dec 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38069422
20.
Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22).
Br J Cancer
; 127(8): 1479-1486, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35869143